Holocene Advisors
ALXN

Holocene Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Holocene Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,211
Closed -$246K – 775
2018
Q1 		$246K Sell
2,211
-2,012
-48% -$240K 0.01% 458
2017
Q4 		$505K Buy
+4,223
New +$514K 0.01% 411

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Holocene Advisors's ALXN Position: Q2 2018 in Review

Holocene Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,211 shares — an estimated $246K sold.

Holocene Advisors first reported a position in ALXN in Q4 2017 and held it in 2 quarters. The position peaked at $505K in Q4 2017. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Holocene Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Holocene Advisors sold 2,211 Alexion Pharmaceuticals shares in Q2 2018, an estimated $246K.
  • Holocene Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Holocene Advisors's Alexion Pharmaceuticals position peaked at $505K in Q4 2017.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Holocene Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.